Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bone Neoplasms
Breast Neoplasms
Evaluation Studies as Topic
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Receptors, Estrogen
Receptors, Progesterone
Soft Tissue Neoplasms
Survival Rate
Tamoxifen

authors with profiles

Olwen Hahn